IRWD Reports $273M LINZESS Net Sales, $107M Total Revenue, $41M GAAP Net Income, +97% YoY Growth, sNDA Accepted, May 24 PDUFA, Apraglutide Phase 3 Initiation Q2
Ironwood Pharmaceuticals, Inc. - Class A · PHARMACEUTICAL PREPARATIONS · Now $3.46
-16% in 7d after detection
Post-detection moves
1h
—
1d
+1.2%
3d
-1.9%
7d
-16%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS